Influenza Viral Infections Clinical Trial
— GP-FluRecallOfficial title:
Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician - a Cluster Randomized, Controlled and Pragmatic Trial
This study is a clinical trial designed to assess the impact on influenza vaccination rates among people aged over 65 of a telephone text message recalling them to be vaccinated by their GP. Twenty-two GPs will be randomly selected in each arm (recall versus usual care, 1:1). Each GP will include a maximum of 210 patients by random selection from their patient list. A difference of 4 percentage points is expected between the two arms at the end vaccination campaign in the vaccination rate.
Status | Recruiting |
Enrollment | 8400 |
Est. completion date | February 28, 2025 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: The inclusion criteria for physicians are: - To be a GPs - To be based in Ile-de-France (Paris region, France) - To be a user of the Eo medical software The patients inclusion criteria are: - belonging to the list of attending physicians of the participating GPs - being 65 years of age or older - having a medical file in the GP's Eo medical software - having been selected at random if the number of patients aged 65 or over exceeds 210 patients (for 44 participating GPs). Exclusion Criteria: - Patients for which their attending physicians considers participating inappropriate (e.g. palliative care) |
Country | Name | City | State |
---|---|---|---|
France | Cabinet medical Lahire (01) | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The influenza vaccination rate will be calculated as the ratio between the number of patients vaccinated (those who will report having been vaccinated in the questionnaire send at the end of the campaign) and the number of patients aged 65 years and over | The influenza vaccination rate will be calculated as the ratio between the number of patients vaccinated (i.e., those who will report having been vaccinated during the vaccination campaign in the questionnaire send at the end of the campaign) and the number of patients aged 65 years and over. | 12 months | |
Secondary | 1/ Social inequalities related to the intervention, based on individual and ecological indicators (social deprivation index for example) will be estimated via absolute indicators (SII: slope of the inequality index) and relative (RII: relative inequality | At the end of the vaccination campaign, the GPs will send patients a postal mail containing: an accompanying explanatory letter, the patient questionnaire, and a pre-addressed and prepaid envelope for the return of the completed questionnaire to their attending physician. | 1 year | |
Secondary | 2/ Acceptability of reminders (in the intervention arm only) based on the description of the patients answers to the related question in the questionnaires. This outcome is assessed by questionnaire. | At the end of the vaccination campaign, the GPs will send patients a postal mail containing: an accompanying explanatory letter, the patient questionnaire, and a pre-addressed and prepaid envelope for the return of the completed questionnaire to their attending physician. | 1 year | |
Secondary | 3/ Reasons for non-vaccination will be described (stratified by trial arm) based on the description of the patients answers to the related question in the questionnaires.This outcome is assessed by questionnaire. | Reasons for non-vaccination will be described (stratified by trial arm) based on the description of the patients answers to the related question in the questionnaires. | 1 year | |
Secondary | 4/ Characteristics of participating GPs based on the description of the physicians answers to the related question in the questionnaires. These outcomes are assessed by the physician questionnaire. | At the beginning of the study, participating GPs will answer a short questionnaire about their main characteristics (Sex, Date of birth, Size of the patients list...). | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05869201 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
|
Phase 2/Phase 3 | |
Completed |
NCT02103023 -
Intradermal Influenza Vaccine in the Young
|
Phase 3 | |
Completed |
NCT05234229 -
Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
|
||
Completed |
NCT04623047 -
Infection Watch Study
|
||
Not yet recruiting |
NCT02465190 -
Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa
|
N/A | |
Completed |
NCT05620953 -
Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
|
||
Recruiting |
NCT05739474 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children
|
Phase 3 | |
Active, not recruiting |
NCT05794412 -
Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
|
||
Recruiting |
NCT05557539 -
Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach
|
N/A | |
Completed |
NCT03813966 -
Nasal Swab Home Collection Kit (NSHC Kit) Study
|
||
Terminated |
NCT05105191 -
Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room
|
N/A | |
Not yet recruiting |
NCT06247059 -
Reducing Respiratory Virus Transmission in Bangladeshi Classrooms
|
N/A | |
Not yet recruiting |
NCT06175468 -
Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease
|
Phase 3 | |
Active, not recruiting |
NCT01666782 -
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
|
Phase 2 | |
Completed |
NCT05507567 -
Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model
|
Phase 2 | |
Active, not recruiting |
NCT04998344 -
An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh
|
Phase 4 |